BiondVax Pharmaceuticals (BVXV) Stock Price, News & Analysis

Company Overview

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.26 to $1.59
• 52-Week Range: N/A
• Volume: 23,000 shs
• Average Volume: 127,289 shs
• Market Capitalization: $2.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BVXV Stock Analysis - Frequently Asked Questions

How were BiondVax Pharmaceuticals' earnings last quarter?

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) issued its quarterly earnings data on Monday, March, 28th. The company reported ($2.70) EPS for the quarter, missing the consensus estimate of ($0.90) by $1.80.

When did BiondVax Pharmaceuticals' stock split?

BiondVax Pharmaceuticals's stock reverse split before market open on Friday, November 25th 2022.The 1-10 reverse split was announced on Friday, November 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, November 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did BiondVax Pharmaceuticals IPO?

BiondVax Pharmaceuticals (BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

What other stocks do shareholders of BiondVax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BiondVax Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Bristol Myers Squibb (BMY), Gilead Sciences (GILD), Corbus Pharmaceuticals (CRBP) and Pluristem Therapeutics (PSTI).

Company Calendar

• Last Earnings: 3/28/2022
• Today: 7/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BVXV
• CIK: 1611747
• Web: www.biondvax.com
• Phone: 9723029302529
• Fax: 972-8930-2531
• Employees: 33
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.80 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -346.36%
• Return on Assets: -29.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.12
• Quick Ratio: 4.12

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.81) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,870,000
• Free Float: 1,755,000
• Market Cap: $2.54 million
• Optionable: Not Optionable
• Beta: 2.37